Deep Transcranial Magnetic Stimulation for Stimulants Use Disorder

Not Applicable

Completed

• Conditions: Stimulants Use Disorder
• Interventions: Device: H7-Coil Deep TMS for CUD

• Registration Number: NCT05274828
• Lead Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Brief Summary

The purpose of the study is to explore the Feasibility, Tolerability and Safety of the H7-Coil deep Transcranial Magnetic Stimulation for Subjects with Stimulants Use Disorder (SUD).

Detailed Description

Stimulants Use Disorder (SUD) is a major public health issue, with potentially severe psychosocial and medical consequences. Even though psychosocial therapies exist, an important proportion of patients do not respond to these approaches, and no approved biological approaches are currently available. deep TMS (dTMS) has been shown effective for Major Depressive Disorder, Obsessive Compulsive Disorder and Nicotine Use Disorder and could also prove available for SUD. Several pilot studies have shown preliminary effectiveness in SUD, but are limited by the length of their protocol, which could result in limited real-world effectiveness secondary to high dropout rates. Given that aTMS protocols have been applied successfully in MDD, we propose to implement this approach for SUD, in order to reduce treatment length and therefore increase retention rates. We will also gather preliminary data on various biomarkers that could help predict response and better understand biological mechanisms behind SUD.

Study Timeline

• Study First Submitted: 2022-02-16
• Study First Submitted QC: 2022-03-01
• Study First Posted: 2022-03-11
• Study Start: 2022-11-02
• Primary Completion: 2023-12-31
• Status Verified: 2024-04
• Study Completion: 2024-04-01
• Last Update Submitted: 2024-04-16
• Last Update Posted: 2024-04-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Being diagnosed with SUD (moderate or severe) based on DSM-5 criteria
• Current stimulants use with last use in the two weeks prior to admission to the study as confirmed by the Timeline Followback Questionnaire
• Wanting to stop the intake of stimulants
• Being able and willing to adhere to the treatment schedule
• Filling the criteria of the TMS adult safety screening (TASS) questionnaire
• Being voluntary and competent to consent to treatment
• Ability to speak and read French or English

Exclusion Criteria

• Severe psychiatric condition (history of schizophrenia, schizoaffective disorder or bipolar disorder); current acute psychosis, mania or active suicidality (unipolar major depression, anxiety disorders and personality disorders will be allowed as long as they are not primary and causing greater impairment than SUD)
• Severe and/or unstable medical illness, including but not limited to any neurologic, cardiac, renal or hepatic condition
• Implanted medical device (including but not limited to intracranial implants, cardiac pacemaker, medication pump, etc.) or intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed
• Clinically significant laboratory abnormality, in the opinion of the principal investigator
• Pregnancy or breastfeeding
• Another current severe substance use disorder (except nicotine)
• Anti-craving medication and other psychotropic medications are allowed, but need to have been stable for four (4) weeks before screening
• Currently taking more than lorazepam 2 mg daily (or equivalent) or any dose of an anticonvulsant due to the potential to limit TMS efficacy.
• Non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with the interview)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
H7-Coil Deep TMS Treatment	H7-Coil Deep TMS for CUD	H7-Coil Deep TMS Treatment

Primary Outcome Measures

Name	Time	Method
Feasibility-related endpoints - adherence to dTMS	after 10 days of treatment sessions	Number of completer treatment sessions
Adverse Events reported	up to three months after end of the treatment	Adverse events reported
Feasibility-related endpoints - retention rates	after 10 days of treatment sessions	Number of patients who did not completed the total (40) sessions

Secondary Outcome Measures

Name	Time	Method
Percentage change on General Anxiety Disorder (GAD-7)	T0 (week 0), T2 (week 4), T3 (week 6), T4 (week 14)	Percentage change on General Anxiety Disorder (GAD-7)
Percentage change on Stimulants Selective Severity Assessment	T0 (week 0), T1 (end of treatment, week 2), T2 (week 4), T3 (week 6), T4 (week 14)	Percentage change on Stimulants Selective Severity Assessment (Minimum score 0 and Maximum score 126, higher score means worse outcome in terms of substance withdrawal symptoms)
Percentage change on Stimulants Craving Questionnaire	T0 (week 0), T1 (end of treatment, week 2), T2 (week 4), T3 (week 6), T4 (week 14)	Percentage change on Stimulants Craving Questionnaire
Percentage of Positive Urine Drug Screen to Stimulants	up to three months after end of the treatment	Presence of Stimulants in the Drug Screen Panel
Percentage change on Patient Health Questionnaire (PHQ-9)	T0 (week 0), T2 (week 4), T3 (week 6), T4 (week 14)	Percentage change on Patient Health Questionnaire (PHQ-9)

Trial Locations

Locations (1)

Centre Hospitalier de l'Université de Montréal; 🇨🇦 Montréal, Quebec, Canada